Icotrokinra (acetate)

Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].

C90H120N20O22S2·xC2H4O2

CC(O)=O.NCCOC(C=C1)=CC=C1C[C@H](NC([C@H]2NC([C@@H](NC([C@@H](NC([C@](NC([C@@H](NC([C@H](C(C)(SSC2(C)C)C)NC(C)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)CC(C3=CC=C4)=CNC3=C4C)=O)CCCCNC(C)=O)=O)=O)C(N[C@@H](CC5=CC6=C(C=CC=C6)C=C5)C(NC7(CCOCC7)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N(C)CC(N)=O)=O)CC8=CN=CC=C8)=O)=O)=O)=O)=O.[x]

IFNAR; Interleukin Related; STAT

IL-23

99.65

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Blue Ice